Suppr超能文献

亨德拉病毒附着糖蛋白中的单氨基酸取代可诱导产生针对尼帕病毒的交叉中和抗体。

Single amino acid substitution in Hendra virus attachment glycoprotein induces cross-neutralizing antibodies against Nipah virus.

作者信息

Li Yaohui, Huang Xiaoyan, Li Ruihua, Zai Xiaodong, Yang Yilong, Zhang Yue, Zhang Zhang, Zhang Jun, Xu Junjie, Chen Wei

机构信息

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

出版信息

Signal Transduct Target Ther. 2025 Aug 29;10(1):276. doi: 10.1038/s41392-025-02370-0.

Abstract

Nipah virus (NiV) and Hendra virus (HeV) are highly pathogenic henipaviruses within the Paramyxoviridae family, causing severe respiratory and neurological diseases in humans and animals with fatality rates up to 75%, and no licensed human vaccines or therapeutics. In this study, we identified a unique vulnerable epitope on the NiV attachment glycoprotein (G) recognized by the potent neutralizing antibody 14F8, which targets a receptor-binding site and neutralizes NiV effectively. Using the 2.8 Å crystal structure of the 14F8 Fab-NiV-G complex as a guide, we reconstructed this epitope on HeV-G via a single amino acid substitution (S586N), creating the HeV-G mutant. Immunization with HeV-G in BALB/c mice and cynomolgus monkeys elicited robust, broadly neutralizing antibody responses against both NiV and HeV, achieving higher NiV-neutralizing titers post-prime compared to wild-type HeV-G, as confirmed by pseudovirus and live-virus assays. Crystal structures of HeV-G (3.3 Å) and its 14F8 complex (3.2 Å) showed the S586N substitution induced a 9 Å conformational rearrangement in β-propeller blade 6, reshaping the molecular skeleton and solvent-accessible surface without direct N586-14F8 interaction, thus mimicking the NiV epitope. These findings position HeV-G as a promising broad-spectrum antigen for henipavirus prevention and demonstrate the value of structure-guided epitope reconstruction in universal vaccine design for emerging viral threats.

摘要

尼帕病毒(NiV)和亨德拉病毒(HeV)是副粘病毒科中高致病性的亨尼帕病毒,可在人类和动物中引起严重的呼吸道和神经系统疾病,致死率高达75%,且目前尚无获批的人类疫苗或治疗方法。在本研究中,我们在NiV附着糖蛋白(G)上鉴定出一个独特的易损表位,该表位可被强效中和抗体14F8识别,14F8靶向一个受体结合位点并能有效中和NiV。以14F8 Fab-NiV-G复合物的2.8 Å晶体结构为指导,我们通过单个氨基酸取代(S586N)在HeV-G上重建了该表位,从而产生了HeV-G突变体。用HeV-G对BALB/c小鼠和食蟹猴进行免疫,引发了针对NiV和HeV的强大、广泛的中和抗体反应,与野生型HeV-G相比,初次免疫后获得了更高的NiV中和滴度,这通过假病毒和活病毒试验得到证实。HeV-G(3.3 Å)及其14F8复合物(3.2 Å)的晶体结构表明,S586N取代在β-螺旋桨叶片6中诱导了9 Å的构象重排,重塑了分子骨架和溶剂可及表面,且N586与14F8没有直接相互作用,从而模拟了NiV表位。这些发现使HeV-G成为一种有前景的用于预防亨尼帕病毒的广谱抗原,并证明了结构导向的表位重建在针对新出现病毒威胁的通用疫苗设计中的价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5167/12394453/1910a7250f96/41392_2025_2370_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验